医药导报Issue(7)：871-874,875,5.DOI:10.3870/yydb.2015.07.006
YC-1体外调控卵巢癌化学治疗敏感性
In vitro Reguation of YC-1 on the Chemotherapy Sensitivity of Ovarian Cancer
摘要
Abstract
Objective To investigate the contribution of hypoxia-inducible factor inhibitor YC-1 to cisplatin chemo-sensitivity to human ovarian cancer cells A2780s in vitro. Methods Ovarian cancer cells were divided into four groups which were treated with saline, YC-1, cisplatin, and YC-1+cisplatin, separately, mRNA of HIF-1αand VEGF in the A2780s cells were detected by real-time fluorescence quantitative PCR by calculating 2-△△CT;the protein were detected by Western blot, to evaluate the change of hypoxia and angiogenesis capabilities under the ovarian cancer microenvironment. Results Compared with the control group, mRNA and protein of HIF-1αand VEGF expressed less in the group of YC-1, cisplatin and YC-1+cisplatin;while, those in the group of YC-1+cisplatin were lower than the monotherapy (P<0. 05), but no significant difference was detected between the YC-1 and cisplatin groups, and the expression of HIF-1αand VEGF mRNA were positively related(r=0. 830 5)in each group. Conclusion YC-1 exerts the antitumor effect and may contribute to sensitivity to cisplatin in the therapy of ovarian cancer.关键词
3-(5'-羟甲基-2'-呋喃基)-1-苯甲基吲唑/缺氧诱导因子/癌,卵巢/顺铂/耐药Key words
1-Benzyl-3-( 5-hydroxymethylfur-2-yl ) indazole/Hypoxia-inducible factor/Cancer, ovarian/Cisplatin/Chemo-resistance分类
医药卫生引用本文复制引用
黄金玲,洪莉,洪莎莎,闵洁,胡鸣,赵杨,杨青..YC-1体外调控卵巢癌化学治疗敏感性[J].医药导报,2015,(7):871-874,875,5.基金项目
湖北省自然科学基金资助项目(2010CDB06903) （2010CDB06903）
